CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Revenues:
Premiums earned, net (Net of ceded premiums of $122 and $119, for the three months ended March 31, 2023 and 2022, respectively)		$ 317,086	$ 278,169
Non-Insurance revenue		205,783	594,898
Other income		4,906	1,312
Total revenues		527,775	874,379
Operating expenses:
Net medical claims incurred		472,490	861,722
Salaries and benefits		70,207	69,091
General and administrative expenses		59,215	57,697
Premium deficiency reserve benefit		(1,810)	(27,476)
Depreciation and amortization		279	826
Total operating expenses		600,381	961,860
Loss from operations		(72,606)	(87,481)
Interest expense		0	403
Gain on investment		0	(12,394)
Net loss		$ (72,606)	$ (75,490)
Per share data:
Net loss per share attributable to Class A and Class B common stockholders - basic (in dollars per share)	[1]	$ (0.15)	$ (0.16)
Net loss per share attributable to Class A and Class B common stockholders - diluted (in dollars per share)	[1]	$ (0.15)	$ (0.16)
Weighted average number of common shares outstanding
Basic weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	478,805,067	473,028,651
Diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (in shares)	[1]	478,805,067	473,028,651
Net unrealized gain (loss) on available-for-sale investments		$ 2,343	$ (5,324)
Comprehensive loss		$ (70,263)	$ (80,814)

[1] (1) Because the Company had a net loss during the three months ended March 31, 2023 and 2022, the Company's potentially dilutive securities, which include stock options, restricted stock, preferred stock, and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.